Mutations in ZRSR2 have been linked with disease progression in patients with JAK2 V617R – driven myeloproliferative ...

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 CY2025 results topping the market’s revenue ...

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...

Best known for its blockbuster drug Jakafi and expanding oncology pipeline, this biotech combines profitability, pipeline ...